Milestone Scientific Inc. (MLSS) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly report (Form 10-Q) for Milestone Scientific Inc. for the period ended June 30, 2024. Milestone is a biomedical technology company developing computer-controlled injection devices for dental and medical markets. Key products include the STA Single Tooth Anesthesia System (dental) and the CompuFlo Epidural Computer Controlled Anesthesia System (medical). The company operates as a smaller reporting company and relies on third-party manufacturers for production.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Net Product Sales | $1,853,764 | $4,102,609 | $2,909,966 | $5,507,564 |
| Gross Profit | $1,411,204 | $3,087,307 | $1,890,059 | $3,778,682 |
| Gross Margin | 76.1% | 75.3% | 65.0% | 68.6% |
| Operating Loss | $(1,780,423) | $(3,245,491) | $(2,277,550) | $(3,620,226) |
| Net Income (Loss) | $223,638 | $(1,216,891) | $(2,228,828) | $(3,548,159) |
| Cash & Equivalents (End of Period) | $5,752,106 (as of June 30, 2024) | |||
| Working Capital | ~$7.7 million (as of June 30, 2024) | |||
| Operating Cash Flow (YTD) | $(434,473) | $(3,027,126) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased by approximately 36% in Q2 2024 compared to Q2 2023. This was driven by a significant drop in international sales (down ~$710,000) due to freight forwarder issues and the complete cessation of revenue from China ($0 in Q2 2024 vs. $270,000 in Q2 2023).
- Margin Expansion: Despite lower revenue, gross margins improved significantly (76.1% in Q2 2024 vs. 65.0% in Q2 2023). This is attributed to the shift toward a direct-to-consumer E-Commerce model, which offers higher margins than distributor sales.
- Profitability Shift: The company reported a net income of $223,638 for Q2 2024, a reversal from a net loss of $2.2 million in the same period last year. This was primarily due to a one-time Gain on sale of net operating losses (NOLs) of $1,983,095 recognized in April 2024.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased by approximately $1.1 million year-over-year, driven by lower headcount and reduced stock-based compensation.
Guidance, Outlook, and Risks
- Liquidity: Management forecasts that current cash and liquidity ($5.8 million) are sufficient to finance operations for at least the next 12 months. However, the company has incurred cumulative losses of $124.6 million since inception and will require additional capital to achieve profitability.
- Medical Segment Growth: The company received regulatory approval from Brazil's ANVISA for the CompuFlo system in June 2024. Additionally, a favorable Medicare Part B physician price assignment was granted in Florida in July 2024, potentially accelerating commercial rollout in the U.S.
- Key Risks:
- Manufacturing Concentration: Reliance on informal arrangements with third-party manufacturers (including a related party, United Systems) creates supply chain risks.
- Going Concern: Continued operating losses and the need for future capital raises pose risks to long-term viability.
- NOL Sale Contingency: The $2.0 million gain from the NOL sale is contingent on the company maintaining a physical presence in New Jersey for five years; failure to do so could result in a liability of up to $2.2 million.
Investor Verification Checklist
- NOL Sale Terms: Verify the specific conditions of the New Jersey Technology Business Tax Certificate Transfer Program and the company's ability to maintain the required physical presence for five years.
- China Revenue: Investigate the reasons for the total loss of revenue from China and the status of freight forwarder issues affecting international sales.
- Related Party Transactions: Review the supply agreement with United Systems (controlled by a significant stockholder) and the terms of the royalty sharing agreement with Leonard Osser.
- Inventory Valuation: Confirm the $1.2 million allowance recorded for slow-moving medical finished goods and the strategy for commercializing the CompuFlo system.
- Capital Needs: Assess the timeline and potential dilution associated with future capital raises required to sustain operations beyond the 12-month forecast.